FLT3 and acute myeloid leukemia: We observed that maintenance sorafenib was superior to prophylactic DLI in FLT3-ITD AML patients, with a lower relapse rate (4.2 vs. 25%) and a lower incidence of grade II–IV aGVHD (8.7 vs. 46.3%) (109).